Tamoxifen ('Nolvadex'): a review

被引:182
作者
Clemons, M
Danson, S
Howell, A
机构
[1] Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada
[2] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England
关键词
Tamoxifen; breast cancer; advanced; early; prevention; ductal carcinoma in situ; mechanism of action; tolerability;
D O I
10.1016/S0305-7372(02)00036-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women. It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:165 / 180
页数:16
相关论文
共 161 条
  • [1] Abram P, 1996, J NATL CANCER I, V88, P1834
  • [2] SEQUENTIAL TREATMENT OF METASTATIC BREAST-CANCER WITH TAMOXIFEN AFTER MEGESTROL-ACETATE THERAPY AND VICE VERSA (A RETROSPECTIVE STUDY)
    ALEXIEVAFIGUSCH, J
    VANPUTTEN, WLJ
    VANGILSE, HA
    BLONKVANDERWIJST, J
    KLIJN, JGM
    [J]. MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1985, 2 (02): : 69 - 75
  • [3] Endocrine-responsive breast cancer and strategies for combating resistance
    Ali, S
    Coombes, RC
    [J]. NATURE REVIEWS CANCER, 2002, 2 (02) : 101 - +
  • [4] ALLEGRA JC, 1985, SEMIN ONCOL, V12, P61
  • [5] RANDOMIZED TRIAL OF TAMOXIFEN VERSUS AMINOGLUTETHIMIDE AND VERSUS COMBINED TAMOXIFEN AND AMINOGLUTETHIMIDE IN ADVANCED POSTMENOPAUSAL BREAST-CANCER
    ALONSOMUNOZ, MC
    OJEDAGONZALEZ, MB
    BELTRANFABREGAT, M
    DORCARIBUGENT, J
    LOPEZLOPEZ, L
    BORRASBALADA, J
    CARDENALALEMANV, F
    GOMEZBATISTE, X
    FABREGATMAYOL, J
    VILADIUQUEMADA, P
    [J]. ONCOLOGY, 1988, 45 (05) : 350 - 353
  • [6] INCIDENCE OF NEW PRIMARY CANCERS AFTER ADJUVANT TAMOXIFEN THERAPY AND RADIOTHERAPY FOR EARLY BREAST-CANCER
    ANDERSSON, M
    STORM, HH
    MOURIDSEN, HT
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (14) : 1013 - 1017
  • [7] [Anonymous], 1988, NEW ENGL J MED, V319, P1681
  • [8] GYNECOLOGIC EFFECTS OF TAMOXIFEN AND THE ASSOCIATION WITH ENDOMETRIAL CARCINOMA
    ASSIKIS, VJ
    JORDAN, VC
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1995, 49 (03) : 241 - 257
  • [9] BAUM M, 1988, BRIT J CANCER, V57, P608
  • [10] RESULTS OF THE CANCER-RESEARCH CAMPAIGN ADJUVANT TRIAL FOR PERIOPERATIVE CYCLOPHOSPHAMIDE AND LONG-TERM TAMOXIFEN IN EARLY BREAST-CANCER REPORTED AT THE 10TH YEAR OF FOLLOW-UP
    BAUM, M
    HOUGHTON, J
    RILEY, D
    MACINTYRE, J
    BERSTOCK, D
    MCKINNA, A
    JACKSON, I
    SAINSBURY, JRC
    WILSON, A
    WHEELER, T
    DOBBS, J
    REES, G
    POWLES, T
    RUBENS, R
    HAYBRITTLE, J
    MCPHERSON, K
    HOUGHTON, J
    [J]. ACTA ONCOLOGICA, 1992, 31 (02) : 251 - 257